Pricing Log in Create free account

NewAmsterdam Pharma Company N.V. (NAMS) vs Pharvaris N.V. (PHVS)

NewAmsterdam Pharma Company N.V. and Pharvaris N.V. are both Biotechnology companies. NewAmsterdam Pharma Company N.V. and Pharvaris N.V. are of similar size ($2.3B and $2.3B). Pharvaris N.V. has the higher net margin (0.00% vs −789.9%) and the higher return on invested capital (0.00% vs −23.1%). Across the 14 metrics below, NewAmsterdam Pharma Company N.V. leads on 8 and Pharvaris N.V. on 6.

Valuation

Metric NAMS PHVS Biotechnology median
P/E n/m n/m 10.26
P/S 91.08 n/m 9.18
P/B 3.75 6.38 2.05
Price to free cash flow n/m n/m 24.81
EV/EBITDA n/m n/m 0.65
EV/Sales 66.59 n/m 8.98
Earnings yield (8.88%) (9.30%) (34.89%)
Free cash flow yield (6.39%) (7.98%) (24.52%)

Profitability

Metric NAMS PHVS Biotechnology median
Gross margin 100.00% 0.00% 65.16%
Operating margin (900.07%) 0.00% 0.00%
Net margin (789.94%) 0.00% 0.00%
Free cash flow margin (581.64%) 0.00% 0.00%
Return on equity (30.16%) (71.50%) (50.12%)
Return on assets (27.79%) (64.43%) (45.60%)
Return on invested capital (23.13%) 0.00% 0.00%

Growth

Metric NAMS PHVS Biotechnology median
Revenue growth (TTM) (26.41%) — 6.26%
EPS growth (last fiscal year) 32.81% (25.37%) 29.88%
Revenue growth, 5-year CAGR — — 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric NAMS PHVS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 11.76 11.94 4.89
Net debt to EBITDA 2.83 1.72 1.01

Dividend

Metric NAMS PHVS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric NAMS PHVS Biotechnology median
Market cap 2.26b 2.28b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack